Suneva has now raised more than $140m in debt and equity in total, and will use the capital to keep commercialising its skincare products.
Suneva Medical, a US-based dermatology and aesthetic product developer that counts pharmaceutical company Almirall as an investor, received $25m in funding from growth equity firm Essex Woodlands on Tuesday.
The investment will support commercial activities for two Suneva products: skin repair product Regenica and Bellafill, a dermal filler used to combat acne scarring and smile lines.
Suneva has now raised about $105m in equity funding, including $15m in series C funding from Almirall in July 2015, and $35m in debt…
